Lupin receives FDA approval for Fluoxetine Tablets USP

Deepthi | Myequity news | Date : 12-02-2019 16:00:00 IST

Pharma major Lupin has received approval for its Fluoxetine Tablets USP, 60mg, from the United States Food and Drug Administration (FDA) to market a generic version of Alvogen’s Fluoxetine Tablets, 60mg.

Lupin’s Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen’s Fluoxetine Tablets, 60mg. It is indicated in the treatment of:

•Major Depressive Disorder (MDD).
•Obsessive Compulsive Disorder (OCD).
•Bulimia Nervosa
•Panic disorder, with or without agoraphobia
Fluoxetine Tablets, 60mg, had annual sales of approximately USD 42.5 million in the US (IQVIA MAT December 2018).


About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


More from Myequity